Drug intelligence / Profile preview

Zynamite S

Development stage
Unknown
Lead developer
Nektium
Modality
Small Molecules
Administration
Oral
01

Overview

Zynamite S is a proprietary, **water-soluble extract of Mangifera indica (mango) leaf**, standardized to contain 60% mangiferin as its main bioactive compound. Developed as a next-generation, **enhanced-bioavailability version of Zynamite**, it was specifically engineered to overcome the poor solubility and low bioavailability of standard mangiferin preparations. Zynamite S has been clinically shown to rapidly improve cognitive domains such as processing speed, attention, working memory, and executive function, with effects observed within 30 minutes of a single dose and lasting up to 5 hours. Mechanistic studies attribute efficacy largely to partial inhibition of catechol-O-methyltransferase (COMT), increasing dopamine levels in the prefrontal cortex, as well as possible acetylcholinesterase (AChE) inhibition, which could potentiate cholinergic neurotransmission. Unlike stimulant products, Zynamite S exerts these benefits with no effect on heart rate or blood pressure. It also demonstrates **meaningful improvement in mood and reduction of negative emotional states**, making it a dual-action nootropic for both cognitive and emotional performance.

Brand names
Zynamite S
Other names
Zyn-SZynamite water-solubleZynamite S monosodium salt
02

Targets

AcetylcholinesteraseCOMT (Catechol-O-methyltransferase)

Beyond the preview

Go deeper on Zynamite S.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zynamite S.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call